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Abstract
Background: The emergence of community-associated methicillin resistant Staphylococcus aureus (CA-MRSA) has caused a
change in MRSA epidemiology worldwide. In the Middle East, the persistent spread of CA-MRSA isolates that were
associated with multilocus sequence type (MLST) clonal complex 80 and with staphylococcal cassette chromosome mec
(SCCmec) type IV (CC80-MRSA-IV), calls for novel approaches for infection control that would limit its spread.
Methodology/Principal Findings: In this study, the epidemiology of CC80-MRSA-IV was investigated in Jordan and Lebanon
retrospectively covering the period from 2000 to 2011. Ninety-four S. aureus isolates, 63 (67%) collected from Lebanon and
31 (33%) collected from Jordan were included in this study. More than half of the isolates (56%) were associated with skin
and soft tissue infections (SSTIs), and 73 (78%) were Panton-Valentine Leukocidin (PVL) positive. Majority of the isolates
(84%) carried the gene for exofoliative toxin d (etd), 19% had the Toxic Shock Syndrome Toxin-1 gene (tst), and seven
isolates from Jordan had a rare combination being positive for both tst and PVL genes. spa typing showed the prevalence of
type t044 (85%) and pulsed-field gel electrophoresis (PFGE) recognized 21 different patterns. Antimicrobial susceptibility
testing showed the prevalence (36%) of a unique resistant profile, which included resistance to streptomycin, kanamycin,
and fusidic acid (SKF profile).
Conclusions: The genetic diversity among the CC80 isolates observed in this study poses an additional challenge to
infection control of CA-MRSA epidemics. CA-MRSA related to ST80 in the Middle East was distinguished in this study from
the ones described in other countries. Genetic diversity observed, which may be due to mutations and differences in the
antibiotic regimens between countries may have led to the development of heterogeneous strains. Hence, it is difficult to
maintain ‘‘the European CA-MRSA clone’’ as a uniform clone and it is better to designate as CC80-MRSA-IV isolates.
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Introduction
Staphylococcus aureus, a highly adaptive and versatile gram-
positive bacterium, is considered one of the most isolated human
pathogens and the most common cause of skin and soft tissue
infections (SSTIs) [1,2]. Soon after the introduction of methicillin
for the treatment of penicillin-resistant strains in 1959, methicillin-
resistant S. aureus (MRSA) has emerged as an important hospital-
associated (HA-MRSA) pathogen for its increased morbidity and
mortality rates, healthcare costs, and length of hospital stay [3,4].
HA-MRSA infections arise in individuals with predisposing risk
factors, such as surgery or presence of an indwelling medical
device. By contrast, many community-associated MRSA (CA-
MRSA) infections arise in otherwise healthy individuals who do
not have such risk factors. CA-MRSA infections are also known to
be epidemic in some countries. These features suggest that CA-
MRSA strains are more virulent and transmissible than are
traditional HA-MRSA strains [5].
CA-MRSA lineages are genotypically and phenotypically
unrelated to the former multi-drug resistant HA-MRSA, and
recently have started replacing the once pandemic HA-MRSA
clones (CC5, 8, 22, 36, and 45) in health care facilities [6,7].
Continent-specific-PVL positive CA-MRSA clones were previous-
ly described: ST1-IV (USA400), ST8-IV (USA300), ST30-IV
(Pacific/Oceania), ST59-IV/V (USA1000, Taiwan), and ST80-IV
(European CA-MRSA) [8], which were also reported from other
parts of the world [9,10,11,12,13].
Common to all lineages is that they are generally susceptible to
non-b-lactam antibiotics, harbor the small-sized staphylococcal
chromosomal cassette mec (SCCmec) types IV or V encoding
methicillin resistance, and carry the Panton-Valentine Leukocidin
(PVL) toxin genes [2,14,15]. European clone ST80-IV (allelic
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profile 1-3-1-14-11-51-10) was first identified in the early 1990s
and today is found throughout Europe, the Middle East, and
Northern Africa [10,16,17,18,19,20]. This clonal lineage is PVL-
positive, belongs to agr type III, has type 8 capsular polysaccha-
ride, and is resistant to tetracycline, streptomycin, kanamycin, and
fusidic acid with a pronounced susceptibility to gentamicin
[18,19,20].
Compared to the CA-MRSA clone most common in the United
States (USA300), the European CA-MRSA clone seems less well
adapted to persist in hospital environments, where CC80-MRSA-
IV has entered Danish hospitals but has not caused nosocomial
infections [18,21]. Several reports indicated the transmission of the
ST80-IV clone to Europe from patients with a recent history of
travel or family relation to the Mediterranean or Middle East
[18,22,23,24,25].
In the Middle East, little information is available about the
emergence and continuous spread of CC80 clone. Khalil et al.
[12] performed molecular characterization of 103 S. aureus
isolates (41 MRSA and 62 MSSA) recovered from stool and nose
specimens collected from children admitted to the University of
Jordan Hospital. Genotyping revealed 48 different spa types and
identified distinct allelic profiles with the majority belonging to
ST80. On the other hand molecular characterization of 130 S.
aureus clinical isolates (93 MRSA and 37 MSSA) recovered from
patients at the Clinical Microbiology Section of the American
University of Beirut in Lebanon revealed the presence of 48 spa
types that clustered into 30 different groups. MLST revealed 10
sequence types (STs) among the isolates, and the majority of the
PVL-positive isolates (53%) were ST80-MRSA-IVc [10]. Howev-
er, a similar more recent study was conducted on 132 S. aureus
non-duplicate clinical isolates recovered in a period of six months
at AUB-MC [11]. MRSA represented 30% of the isolates collected
in this study, with the most common being: t021 (6%), t044 (5%),
and t267 (5%). Clustering SCCmec with MLST identified seven
MRSA and 20 MSSA clones, and confirmed that the PVL-positive
ST80-MRSA-IV was the dominant clone in Lebanon. The present
retrospective study provides data on the epidemiology and
molecular characteristics of ninety-four CC80-MRSA-IV isolates
collected from Lebanon and Jordan over an 11-year period (2000–
2011).
Materials and Methods
Ethical approval
Ethical approval was not required as clinical isolates were
collected and stored as part of routine clinical care. Clinical
isolates and patient records/information were anonymized and de-
identified prior to analysis.
Hospital setting
Isolates from Jordan were obtained from the University of
Jordan Hospital (UJH) in Amman, a governmental hospital that
serves over 500,000 patients annually with a 547-inpatient bed
capacity, while those from Lebanon were collected from the
American University of Beirut Medical Center (AUB-MC) in
Beirut, a private university hospital that provides tertiary services
for over 300,000 patients annually with a 350-inpatient bed
capacity.
Clinical Isolates
S. aureus isolates (n= 478) were collected from Lebanon and
Jordan from 2000 to 2011. Isolates were confirmed as S. aureus by
Gram staining, positive catalase reaction, and production of
coagulase enzyme using SLIDEX Staph Plus agglutination kit
(Biome´rieux, France). All isolates identified to be spa type t044
and/or belonging to spa-clonal cluster 044 (spa-CC 044), were
included in this study. In total 94 isolates (Jordan, n= 31;
Lebanon, n= 63) were undertaken in this study. DNA was
extracted using a Nucleospin Tissue kit (Macherey-Nagel,
Germany) according to manufacturer’s instructions.
Clinical and demographic information
Clinical and demographic data were extracted from patients’
charts and lab discharge summaries and included: specimen origin
(skin and soft tissue, respiratory, blood, stool, etc.), age, gender,
time of isolation and hospitalization criteria (in or out-patient,
surgery, etc.).
Antibiotic susceptibility testing
Antimicrobial susceptibility testing was performed using the
Kirby-Bau¨er disk diffusion method according to Clinical and
Laboratory Standards Institute (CLSI) recommendations [28] for
streptomycin, kanamycin, tetracycline, gentamicin, fusidic acid,
penicillin G, rifampicin, erythromycin, and clindamycin. Discs
were purchased from Oxoid (Oxoids, UK) and Biorad (Bio-Rad,
Marnes-la-Coquette, France) and samples were streaked on
Muller-Hinton agar plates (Oxoids, UK) with an 18–20 hour
incubation at 3561uC. Resistance for fusidic acid (, 24 mm) was
determined according to breakpoints defined by the European
Committee on Antimicrobial Susceptibility Testing (EUCAST)
v3.0. S. aureus ATCC 29213 was used as a quality control strain
to determine assay sensitivity.
Multiplex PCR (M-PCR) for detection of 16S rRNA, PVL,
and mecA genes
Amplification of the 16S rRNA that served as an internal
positive control, PVL (lukS-PV and lukF-PV), and mecA genes
were done as described by McClure et al. [29]. PVL negative
MRSA (N315) and PVL positive MSSA (ATCC 49775) were used
as controls. The amplification reaction contained 1.5 ml of
template DNA in a final volume of 25 ml containing 0.4, 0.8
and 0.8 mM for the primers specific for the 16S rRNA, lukS-PV,
and mecA genes respectively with 2U of AmpliTaq (Fermentas),
1.5 mmol/l MgCl2, 1.6x Taq buffer, 0.2mM of each deoxynu-
cleotide triphosphate (dNTP). The thermocycling conditions were
set at 94uC for 5 min followed by 10 cycles of 94uC for 45 s, 55uC
for 45 s, and 72uC for 75 s and 25 cycles of 94uC for 45 s, 50uC
for 45 s, and 72uC for 75 s PCR products were resolved in a 1.8%
(w/v) Metaphor (Lonza, Rockland, ME, USA) agarose gel in 0.5%
Tris-borate-EDTA buffer (Bio-Rad, Hercules, CA) at 80 V/cm
for 1 hour and were visualized with ethidium bromide.
Toxin gene profiling
Presence of exofoliative toxins a (eta), b (etb), and d (etd), and
staphylococcal Toxic Shock Syndrome Toxin 1 (tst) genes was
determined using previously described PCR primers [29,30,31]
using a single M-PCR reaction. A Qiagen multiplex PCR kit was
used where conditions were first optimized using the following
reference strains: TC-142 (eta positive), TC-7 (etb positive), and
NCTC11963 (tst positive). Reaction mixtures contained 1 mg of
chromosomal template, 25 ml master mix with 3 mM MgCl2, 5 ml
primer mix (2 mM in TE buffer for each primer) and RNase-free
water to a final volume of 50 ml. The optimal cycling conditions
were as follows: 95uC for 15 min; 30 cycles of 94uC for 30 s, 57uC
for 1.5 min, and 72uC for 1.5 min; and a final extension at 72uC
for 10 min.
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MRSA SCCmec typing
SCCmec elements were typed using previously described PCR
primers [32]. For multiplex PCR, a Qiagen multiplex PCR kit was
used, and conditions were optimized using the following reference
strains: MRSA NCTC 10442 (SCCmec I), MRSA N315 (SCCmec
II), MRSA 85/2082 (SCCmec III), MRSA JCSC 4744 (SCCmec
IVa), MRSA JCSC 2172 (SCCmec IVb), MRSA JCSC 47882
(SCCmec IVc), and MRSA WIS (SCCmec V) as previously
described [32,33]. Reaction mixtures contained 1 mg of chromo-
somal template, 25 ml master mix with 3 mM MgCl2, 5 ml primer
mix (2 mM in TE buffer for each primer) and RNase-free water to
a final volume of 50 ml. The optimal cycling conditions were as
follows: 95uC for 15 min; 30 cycles of 94uC for 30 s, 57uC for
1.5 min, and 72uC for 1.5 min; and a final extension at 72uC for
10 min.
spa typing
The polymorphic X region of Staphylococcus protein A (spa)
was amplified for all isolates as previously described [34,35].
Multilocus sequence typing (MLST)
Twenty-four representative isolates were typed by MLST to
confirm their relatedness to the CC80 clone. The isolates were
selected based on variation of specimen origin, year of isolation
and covering all different spa types within spa-CC 044.
Amplification of the seven housekeeping genes (arcC, aroE, glpF,
gmk, pta, tpi, and yqiL) by MLST was done as previously described
[36].
PFGE fingerprinting
All isolates were subjected to PFGE typing using SmaI as
previously described [37]. A bacteriophage lambda ladder PFG
marker (New England BioLabs, UK) was included in each gel and
NCTC 8325 was used as a quality control reference strain.
Data Analysis
spa types were assigned using Ridom Staph Type v2.2.1
database (Ridom GmbH, Wu¨rzburg, Germany) (www.ridom.de/
spaserver/) and clustered into spa clonal clusters (spa-CCs) using
the algorithm based upon repeat pattern (BURP) with clustering
parameters excluding spa types with fewer than five repeats and
grouping spa types to the same spa-CC if the cost was #4. CLC
main workbench software v6.8.4 (CLC bio, Denmark) was used to
assemble and align sequences of the seven housekeeping genes and
sequence types (STs) were determined by submitting the allelic
profile of representative alleles to the MLST database (http://
saureus.mlst.net/) and eBURST v3.0 software was used to
determine the clonal relationship of the isolates with the entire
MLST database. PFGE fingerprints obtained were compared by
means of Dice coefficient, and cluster analysis was performed by
the unweighted pair group method with arithmetic means
(UPGMA) using GelCompar and Bionumerics software v6.5
(Applied Maths, Sint-Martens-Latem, Belgium) with 1% band
tolerance and 0.5% optimization settings. Groups were clustered
according to the recommendations of Tenover et al. [26] and by
applying a similarity coefficient of 80% to all dendrograms as
suggested by Struelens et al. [27].
Categorical comparisons were performed using Chi-square test
(X2). A P value of less than 0.05 was considered to be significant.
The associations between resistance patterns with the sample
origin, gender and site of infection were evaluated using the R
statistical package (v. 3.0.2). The associations of the presence and
absence of the toxins: eta, etb, etd, TSST-1 and PVL with the
sample origin, gender and site of infection were also evaluated.
The function used in R include ‘‘chisq.test()’’ from the package
‘‘stats’’.
Results
Study Population
Ninety-four MRSA isolates identified to be spa type t044 and/
or belonging to spa-clonal cluster 044 (spa-CC 044), and possibly
related to ST80 were included in this study. Isolates were
recovered from Lebanon (n= 63/94 isolates; 67%) and Jordan
(n= 31/94; 33%) from 2000 to 2011 (Table 1 and Table 2).
Around 56% of the isolates were associated with SSTIs, 15% with
respiratory tract infections and 9% with bacteremia. Thirty-one of
the isolates were from Jordan and 63 from Lebanon. Overall, 39%
(n= 37/94) of the isolates were from females and 61% (n= 57/94)
from males.
Characteristics of the MRSA clones
spa typing of all 94 isolates revealed that the majority (85%)
were of spa type t044 (Jordan n= 26/32; Lebanon n= 54/63)
followed by single locus variants (SLV) of type t044 (t131, t5802,
t5849, and t4222) or t131 (t5802), double locus variants (DLV) of
type t044 (t6438 and t9135) and a singleton (t021) (Figure 1).
The isolates selected for MLST typing were chosen based on
variation of specimen origin, year of isolation and covering all
different spa types within spa-CC 044 (Table 1 and Table 2).
MLST typing of these isolates showed that all belonged to ST80
except for one from Jordan, which was ST997. ST997 however, is
also within the CC80 and is a SLV from ST80 (http://saureus.
mlst.net/eburst/database.asp). This isolate, which was recovered
in 2009 from Jordan, was positive for the PVL, etd, and tst genes
and resistant to streptomycin, kanamycin, fusidic acid, erythro-
mycin, and clindamycin (Table 2).
Antibiotic Susceptibility
In this study the common resistance pattern observed was that
of SKF (n= 34/96; 36%) (Table 3). Resistance against strepto-
mycin, kanamycin and fusidic acid was comparable regardless of
the source (Jordan or Lebanon) being 86, 86 and 91%,
respectively. A significant difference was detected between Jordan
and Lebanon with respect to resistance to tertracycline
(p= 0.0017), with the ones from Lebanon showing a higher
resistance rate (n= 22/63; 35% Lebanon vs. n= 6/31; 19%
Jordan). In contrast, the resistance rate against erythromycin
within isolates recovered from Jordan (n= 19/31; 61%) was
higher compared to those from Lebanon (n= 14/63; 22%) and
the difference was also significant (p= 0.000565).
Toxins
PVL genes were detected in 78% (n= 73/94) of the isolates,
with 52% (n= 16/31) of the isolates from Jordan and 8% (n= 5/
63) from Lebanon being PVL-negative (Table 1 and Table 2). eta
toxin gene was only detected in one isolate recovered from wound
in Lebanon, which was additionally PVL positive, while none was
positive for etb. Genetic diversity was additionally observed
between the two set of isolates (Jordan vs. Lebanon) with the etd
and the tst genes, where 64% of the isolates from Lebanon were
positive for etd gene and none for tst compared to 28% for etd gene
and 19% for tst in isolates from Jordan. PVL and TSST-1 were
both found to be significantly associated to the sample origin
(PVL: p= 6.295e-06 and TSST-1: p= 1.136e-10), PVL mainly
detected in isolates from Lebanon and TSST-1 only in isolates
from Jordan, and with the site of infection (PVL: p= 8.726e-05
CC80-MRSA-IV Clone in the Middle East
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Table 1. Demographics and molecular characteristics of isolates collected from Lebanon.
Site of
infection Gender Age1
spa
Type MLST2
Toxin
Profiling3
Antibiotic
Profile4
Wound F 1 t044 80 etd, PVL STR, KAN, TET, FUS, ERY, DA
Wound M 47 t044 80 eta, etd, PVL STR, KAN
Pus F 11 t044 80 etd, PVL STR, KAN, TET, FUS
Wound M 1M t044 80 etd, PVL STR, KAN, FUS
Eye F 70 t131 80 PVL STR, KAN, FUS
Biopsy M 71 t4222 80 etd, PVL STR, KAN, TET, FUS
Wound F 18 t044 80 etd, PVL STR, KAN, FUS, ERY, DA
DTA M 64 t044 80 etd TET, FUS
Pus M 9 t6438 80 etd, PVL STR, KAN, FUS
Bronchial Lavage M 47 t044 80 etd, PVL STR, KAN, FUS
Others F 24 t044 80 etd, PVL STR, KAN, TET, FUS
Abscess M 19 t131 80 etd, PVL Sensitive to all tested antibiotics
Tracheal Aspirate M 6M t021 80 etd STR, KAN, FUS
Wound F 36 t9135 80 etd, PVL STR, KAN, FUS
Abscess M 41 t044 ND etd, PVL STR, KAN, FUS
Abscess F 34 t044 ND etd, PVL STR, KAN, FUS
DTA M 50 t044 ND etd, PVL STR, KAN, FUS
Abscess M 31 t044 ND PVL STR, KAN, FUS
Abscess F 29 t044 ND etd, PVL STR, KAN, FUS
Abscess F 62 t044 ND etd, PVL STR, KAN, FUS
Wound M 18 t044 ND etd, PVL FUS
DTA M 60 t044 ND etd, PVL Sensitive to all tested antibiotics
Wound M 4 t044 ND etd, PVL STR, KAN, TET, FUS
Wound F 57 t044 ND etd, PVL STR, KAN, FUS
Wound M 35 t044 ND etd, PVL STR, KAN, TET, FUS, ERY
Wound F 52 t044 ND etd, PVL STR, KAN, TET, FUS, ERY
Wound M 35 t044 ND etd, PVL STR, KAN, TET, FUS
Wound M 21 t044 ND etd, PVL STR, KAN, TET, FUS
Wound M 74 t044 ND etd STR, KAN, FUS
Wound F 27 t131 ND etd, PVL STR, KAN, FUS
Blood M 72 t044 ND etd, PVL STR, KAN, TET, FUS
Wound M 53 t044 ND PVL STR, KAN, FUS
Wound M 30 t044 ND etd STR, KAN, TET, GEN, FUS, ERY, DA
Catheter F 89 t044 ND etd, PVL STR, KAN, FUS
Wound F 41 t044 ND etd, PVL STR, KAN, FUS, ERY
Wound M 82 t044 ND PVL STR, KAN, FUS
DTA M 72 t044 ND etd, PVL STR, KAN, FUS, ERY
Wound M 78 t044 ND etd, PVL STR, KAN, TET, FUS, ERY
Wound F 42 t044 ND etd, PVL STR, KAN, TET, FUS
Wound F 38 t044 ND etd, PVL STR, KAN, TET, FUS
Wound F 63 t044 ND PVL STR, KAN, FUS
DTA M 74 t044 ND etd, PVL STR, KAN, FUS
Wound M 21 t044 ND etd, PVL STR, KAN, TET, FUS, ERY
Pus F 27 t044 ND etd, PVL STR, KAN, FUS, ERY
Wound M 1 t044 ND etd, PVL STR, KAN, FUS
Pus M 46 t044 ND etd, PVL STR, KAN, FUS, ERY
Wound F 24 t044 ND etd, PVL STR, KAN, FUS, ERY
Blood M 60 t044 ND etd, PVL STR, KAN, FUS
Cyst M 20 t044 ND etd, PVL FUS
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PLOS ONE | www.plosone.org 4 July 2014 | Volume 9 | Issue 7 | e103715
and TSST-1: p= 0.0009773); being higher in isolates from wound,
pus, and abscess versus all other sites of infection. Both toxin genes
were not significantly associated to gender and none of the
remaining toxins was significantly associated to the origin, gender,
or site of infection. Seven of the isolates, all collected from Jordan,
were positive for PVL, tst and etd genes. Six of the isolates were
recovered in 2008 and only one in 2009. There was no correlation
between the isolates’ resistance and PFGE patterns.
One PVL-negative isolate from Lebanon had the common
European antibiotic resistance pattern (TSKF) with additional
resistance to gentamicin, clindamycin, and erythromycin. tst
positive isolates on the other hand, in addition to being resistant
to the b -lactam drugs were resistant to streptomycin, kanamycin,
and fusidic acid. spa typing of all the seven tst positive and MLST
typing of three revealed that all were spa type t044, two were ST80
and one ST977, with all belonging to the CC80 lineage. Finally, a
clear heterogeneity was detected within the other studied toxin
genes too, with 64% of the isolates from Lebanon being positive
for etd gene compared to only 28% for those from Jordan (Table 1
and Table 2).
Overall, 16% (n= 15/94) of the isolates had the same genetic
characteristics as that of the European ST80 (etd positive, PVL
positive, SCCmec-IV and TSKF resistance pattern). It is
noteworthy that all 15 isolates were recovered from Lebanon
(Table 1).
PFGE
PFGE-based analysis clustered the 94 isolates in 21 different
clonal groups when employing 80% as a similarity cutoff value,
with 26% of the isolates clustering in one group designated as
clonal group K (Figure 2, Table 1 and Table 2). This pulsotype
had isolates from both countries, and all except for two isolates
from Jordan were PVL positive, and were of spa types: t044, t131,
and t5849. The genetic diversity occurred during the whole study
period with isolates from both countries showing diversification
and at times coexistence. The diversity between the isolates
recovered from both countries however, was again clearly seen
with the lack of any common pulsotype. Finally, different spa
types, resistance profiles, and toxin genes did not correlate with
specific PFGE subtypes.
Discussion
In Europe, most CA-MRSA isolates were associated with
CC80-IV with the first report detecting an ST80-IV isolate being
in 1998 in Greece [38]. Since then, sporadic ST80-IV cases have
been reported in many European countries, which argued the
possibility of the clone being introduced from the Middle East
[18,21,25,39]. Geographically, the Middle East is a heterogeneous
region composed of 17 countries that vary substantially in terms of
size, population and culture. Several reports from the Middle East
have previously detected and reported the circulation of ST80-IV
clone [10,12,40,41,42,43,44,45]. Understanding the ST80-IV
epidemic in the Middle East and its potential successful
transmission to Europe was an important endeavor towards better
control. Accordingly this study was conducted, which included a
collection of projected CC80 related MRSA recovered from
Lebanon (n= 63/94 isolates; 67%) and Jordan (n= 31/94; 33%)
from 2000 to 2011, in an attempt to determine the relatedness, if it
exists, between the European ST80-IV and the ones prevalent in
the Middle East.
CA-MRSA have been associated primarily with community
acquired infections, predominantly SSTIs, in young people [2].
Having 56% of the isolates in this study associated with SSTIs
agrees with the notion of ST80-IV isolates being primarily
associated with SSTIs in patients outside hospitals [46]. However,
isolates causing invasive infections, including bacteremia (9%) and
respiratory tract infections (15%) were also detected and included.
The most common antimicrobial resistance pattern observed
within ST80 isolates circulating in Europe is the one against
tetracycline, streptomycin, kanamycin and fusidic acid (TSKF
pattern) [18,47]. A different common pattern however, was
Table 1. Cont.
Site of
infection Gender Age1
spa
Type MLST2
Toxin
Profiling3
Antibiotic
Profile4
Wound M 58 t044 ND etd, PVL FUS
Wound F 68 t044 ND etd, PVL STR, KAN, FUS
Pus F 59 t044 ND etd, PVL STR, KAN, TET, FUS
Abscess F 20 t044 ND etd, PVL STR, KAN, FUS, ERY
Biopsy M 72 t044 ND PVL STR, KAN, FUS
Pus M 47 t044 ND etd STR, KAN, FUS
Ear F 45 t044 ND etd, PVL TET, FUS, ERY
Abscess M 28 t044 ND PVL STR, KAN, TET, FUS
Pus F 89 t044 ND PVL STR, KAN, FUS
Eye F 4W t131 ND PVL TET, FUS
Eye M 4W t131 ND PVL TET, FUS
Abdominal Fluid M 24 t044 ND etd, PVL STR, KAN
Pus F 18 t044 ND etd, PVL STR, KAN, TET, FUS
Abscess M 24 t044 ND etd, PVL STR, KAN
1W: weeks; M: months.
2ND: non-determinant.
3eta: exofoliative toxin a gene; etd: exofoliative toxin d gene; PVL: Panton-Valentine Leukocidin gene.
4STR: streptomycin; KAN: kanamycin; TET: tetracycline; GEN: gentamicin; FUS: fusidic acid; ERY: erythromycin; DA: clindamycin.
doi:10.1371/journal.pone.0103715.t001
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detected among the isolates examined in this study, being mainly
that of SKF (n= 34/96; 36%). Resistance against streptomycin,
kanamycin and fusidic acid was comparable regardless of the
source (Jordan or Lebanon) being 86, 86 and 91%, respectively.
Compared to the European ST80 isolates, we detected in general
a higher susceptibility to tetracycline especially with the ones
recovered from Jordan (Lebanon n= 22/63; 35% resistant vs.
n= 6/31; 19% for Jordan). On the other hand, higher resistance
to erythromycin was detected within the isolates from Jordan
(n= 19/31; 61%) as compared to those from Lebanon (n= 14/
63; 22%). Similarly, Udo and Srakhoo [45] also showed the
presence of variations in the resistance patterns between isolates
recovered from Kuwait when compared to the European ST80
clone. This diversity reflects differences in the treatment regimens
that exist between those countries.
PVL, a prophage-encoded bi-component pore-forming protein,
is encoded by two genes: lukS-PV and lukF-PV residing in
genomes of some bacteriophages (e.g.: WSa2958, WSa2MW,
WPVL) and these are readily transferrable following selective
bacterial infection [48]. At elevated concentrations, PVL causes
host cell lysis; however at lower concentrations, PVL primes
neutrophils to release inflammatory mediators such as leukotriene
B4, IL-8, granule contents and reactive oxygen species [49].
Although its role in pathogenicity remains controversial, many
murine-conducted studies show the role of PVL in mitochondrial
inactivation and apoptosis as well as its association with certain
established diseases such as necrotizing pneumonia and SSTIs
[2,50,51]. PVL genes were detected in 78% (n= 73/94) of the
isolates. Contrary to the European PVL-positive ST80, 52%
(n= 16/31) of the isolates from Jordan and 8% (n= 5/63) from
Lebanon were PVL-negative. PVL-negative ST80 was previously
Table 2. Demographics and molecular characteristics of isolates collected from Jordan.
Site of
infection Gender Age1
Spa
Type MLST2
Toxin
Profile3
Antibiotic
Profile4
Nose F 4M t044 80 etd, tst STR, KAN, FUS, ERY
Stool M 12M t044 80 etd, tst STR, KAN, FUS
Nose M 16D t044 80 etd, tst, PVL STR, KAN, TET, FUS, ERY
Nose M 12M t131 80 etd, tst STR, KAN, FUS
Nose M 1M t5849 80 etd, tst STR, KAN, FUS, ERY
Wound F 31 t044 80 etd, PVL STR, KAN, TET, FUS
Wound M 22 t044 80 etd, tst, PVL STR, KAN, FUS, ERY
Ear M 17 t5802 80 PVL STR, KAN, FUS, ERY
Pus F 12 t5849 80 etd, PVL STR, KAN, FUS, ERY
Gall Bladder M 25 t044 997 etd, tst, PVL STR, KAN, TET, FUS, ERY, DA
Stool M 26D t044 ND - STR, KAN, FUS, ERY
Stool F 4M t044 ND etd, tst STR, KAN, FUS, ERY
Nose M 12M t044 ND etd, tst STR, KAN, FUS, ERY
Stool M 1M t044 ND etd, tst STR, KAN, FUS
Stool M 2M t044 ND etd, tst STR, KAN, FUS, ERY
Nose F 15D t044 ND etd, tst STR, KAN, FUS
Stool F 15D t044 ND etd, tst STR, KAN, FUS
Nose M 15D t044 ND etd, tst STR, KAN
Abdominal Fluid F 89 t044 ND etd, tst, PVL STR, KAN, TET, FUS
Gall Bladder F 37 t044 ND etd, PVL STR, KAN, FUS, ERY
Blood M 33 t044 ND etd, PVL STR, KAN, TET, FUS, ERY
Blood M 29 t044 ND - TET, FUS
Blood F 43 t044 ND etd, PVL STR, KAN, FUS
Peritoneal Fluid M 45 t044 ND - ERY
Blood M 66 t044 ND - FUS, ERY
Pus M 1D t044 ND etd, tst, PVL STR, KAN, FUS, ERY
Wound F 35 t044 ND etd, PVL STR, KAN, FUS, ERY, DA
Blood M 52 t044 ND etd, tst, PVL STR, KAN, FUS
Nose M 40 t044 ND etd, PVL STR, KAN, FUS
Wound F 35 t044 ND etd, tst, PVL STR, KAN, FUS, ERY, DA
Blood M 64 t6438 ND etd ERY, DA
1D: days; W: weeks; M: months.
2ND: non-determinant.
3etd: exofoliative toxin d gene; tst: toxic shock syndrome toxin 1 gene; PVL: Panton-Valentine Leukocidin gene.
4STR: streptomycin; KAN: kanamycin; TET: tetracycline; FUS: fusidic acid; ERY: erythromycin; DA: clindamycin.
doi:10.1371/journal.pone.0103715.t002
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detected in Kuwait [45], Algeria [52], Switzerland and France
[53]. Whether these isolates arose from PVL positive ones due to
the loss of the PVL phage or represent native ST80 backgrounds
that had not previously acquired the PVL phage is something that
needs to be further clarified. It is however noteworthy, that a PVL-
negative isolate from Lebanon had the common European
antibiotic resistance pattern (TSKF) with additional resistance to
gentamicin, clindamycin, and erythromycin. This finding was in
line with the study conducted by Ramdani-Bouguessa et al. [54]
from Algeria, thus posing a problem of having a possibility of
ST80 invading hospital settings that adds an additional significant
threat to public health. Finally, two out of the four isolates that
were both PVL and etd negative were recovered from blood and
were of spa type t044 and SCCmec-IV. Previously Adler et al. [40]
demonstrated that PVL negative and SCCmec-IV S. aureus
isolates were associated with pediatric HA-MRSA bloodstream
infections.
Another significant finding adding up to the observed genetic
diversity within the isolates undertaken in this study at one hand
and the European ST80-IV on the other, was the detection of both
tst and PVL genes in seven of the isolates that were recovered from
Jordan. TSST-1 is a superantigen that stimulates the release of
large amounts of proinflammatory factors in human infection, has
been associated with human toxic shock syndrome [55], and
causes sepsis by uncontrolled stimulation of T lymphocytes
triggering a cytokine storm [56]. TSST-1 element is carried on a
pathogenicity island known now as Sapl1, carrying the tst and
other virulence factors [57]. A single strain of S. aureus rarely
produces both PVL and TSST-1 [58]. However, Holmes et al.
[59] previously documented the tst genes in four of 30 PVL-
positive isolates. All the isolates were typed and belonged to
lineages CC30, CC5 and CC22 some of which were multi-drug
resistant. Similarly, tst positive isolates in this study, in addition to
being resistant to the b-lactam drugs were resistant to streptomy-
cin, kanamycin, and fusidic acid. spa typing of all the seven and
MLST typing of three revealed that all were spa t044, two were
ST80 and one ST997, with all belonging to the CC80 lineage.
Our finding was in line with a recent study in Jordan in which two
putative ST80-IV isolates belonging to spa type t044 harbored
both the PVL and tst genes [41]. Zhi et al. [58] showed that a
PVL-carrying phage from strain MSSA 68111, which was positive
for both PVL and tst genes, was a variant of icosahedral-head type
phage FPVL. These findings suggested that FPVL and
FPVLv68111 might have evolved from a common ancestor and
that genetic drift may have occurred in one or both. Features
unique to FPVLv68111 may have permitted MSSA68111 to
Figure 1. Population snapshot based on BURP analysis of all
recovered spa types. Each dot represents a unique spa type. The
diameter of the a dot is proportional to the quantity of the
corresponding spa type. Blue dot represents group founder, defined
as the spa type with the highest founder score within a CC.
doi:10.1371/journal.pone.0103715.g001
Table 3. Percentage distribution of resistance patterns.
Profile
number Antibiogram1 Lebanon (%) Jordan (%) Total (%)
1 STR, KAN, FUS 26 (41) 8 (26) 34 (36)
2 STR, KAN, FUS, ERY 6 (10) 11 (35) 17 (18)
3 STR, KAN, TET, FUS 12 (19) 2 (6) 14 (15)
4 STR, KAN, TET, FUS, ERY 4 (6) 2 (6) 6 (6)
5 TET, FUS 3 (5) 1 (3) 4 (4)
6 STR, KAN 3 (5) 1 (3) 4 (4)
7 STR, KAN, FUS, ERY, DA 1 (2) 2 (6) 3 (3)
8 FUS 3 (5) - 3 (3)
9 STR, KAN, TET, FUS, ERY, DA 1 (2) 1 (3) 2 (2)
10 TET, FUS, ERY 1 (2) - 1 (1)
11 STR, KAN, TET, GEN, FUS, ERY, DA 1 (2) - 1 (1)
12 FUS, ERY - 1 (3) 1 (1)
13 ERY, DA - 1 (3) 1 (1)
14 ERY - 1 (3) 1 (1)
1STR: streptomycin; KAN: kanamycin; TET: tetracycline; GEN: gentamicin; FUS: fusidic acid; ERY: erythromycin; DA: clindamycin.
doi:10.1371/journal.pone.0103715.t003
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acquire the genes for TSST-1 production. Whether a similar
genetic drift led to having isolates positive for both toxins in those
isolates from Jordan needs to be further investigated, specially that
it was a significant deviation from the norm and that it indicated
the emergence of hypervirulent S. aureus strains. Finally, a clear
heterogeneity was additionally detected within the other studied
toxin genes, with 64% of the isolates from Lebanon being positive
for etd gene compared to only 28% for those from Jordan;
detecting etd toxin gene is a common finding within the European
ST80 isolates [18,53,60], which emphasizes again that ST80-IV
should be considered as a clonal lineage. Yamaguchi et al. [61],
showed that the etd gene was carried on a pathogenicity island and
hypothesized that ETD may play a pathogenic role in a variety of
infections by destroying epithelial barriers, helping bacteria to
spread or invade tissues. This could partly explain the success of
the isolates within some of the ST80 isolates, which usually carried
the gene for ETD in combination with the gene for PVL [59].
The most common spa type so far detected within the CC80-
MRSA-IV isolates has been type t044 (spa repeat pattern r07 r23
r12 r34 r34 r33 r34) in Europe [53,62,63,64,65], Africa
[17,20,43,66], and Asia [10,12,44]. spa typing of the isolates in
this study revealed the following types: t044, single locus variants
(SLV) of type t044 (t131, t5802, t5849, and t4222) or t131 (t5802),
double locus variants (DLV) of type t044 (t6438 and t9135) and a
singleton (t021 annotated to CC30). spa type t131 was frequently
reported among CC80-MRSA-IV isolates from Europe
[18,21,64,65]. It is noteworthy however, that one isolate within
the spa type t131, which also belonged to the ST80-IV and was
positive for PVL and etd genes, showed no resistance to any of the
tested antibiotics. This was in contrast to what was recently
reported by Hadjihannas et al. [65], with a similar isolate
recovered from Greece belonging to the ST80-IVc and spa type
(t131), but expressing an increase in resistance repertoire to
include five different classes of non–b-lactam antibiotics, namely,
quinolones, macrolides, clindamycin, fusidic acid, and tetracy-
clines again re-emphasizing the existing genetic diversity within
ST80-IV clonal lineage.
All isolates chosen for MLST typing, based on variation of
specimen origin, year of isolation and covering all different spa
types within spa-CC 044, were ST80 except for one from Jordan,
which was ST997. ST997 however, is also within the CC80 and is
a SLV from ST80 (http://saureus.mlst.net/eburst/database.asp).
PFGE-based analysis clustered the 94 isolates in 21 different
clonal groups when employing 80% as a similarity cutoff value,
with 26% of the isolates clustering in one group designated as
clonal group K. This pulsotype had isolates from both countries,
all except for two isolates from Jordan were PVL positive, and
isolates were of spa types: t044, t131, and t5849. Different spa
types, resistance profiles, and toxin genes did not correlate with
specific PFGE subtypes. The diversity observed within the isolates
recovered from both countries along with the lack of any common
pulsotype, diminishes the possibility of cross transmission.
European CA-MRSA has previously been described as a rather
uniform clone. However, the high degree of molecular diversity
observed in recent years, and being additionally supported by the
diversity observed in this study, makes it difficult to maintain ‘‘the
European CA-MRSA clone’’ as a uniform clone, and it is better to
refer to them, and as suggested previously, as CC80-MRSA-IV
isolates [18]. Close surveillance of these strains is essential to
monitor their spread, antimicrobial resistance profiles, and
association with disease. Finally, the successful expansion of
ST80 and the heterogeneity observed in this study calls for novel
approaches in infection control measures to monitor their spread.
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